

FXN Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP6409b**Specification****FXN Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q16595](#)**FXN Antibody (C-term) Blocking Peptide - Additional Information****Gene ID 2395****Other Names**

Frataxin, mitochondrial, Friedreich ataxia protein, Fxn, Frataxin intermediate form, i-FXN, Frataxin(56-210), m56-FXN, Frataxin(78-210), d-FXN, m78-FXN, Frataxin mature form, Frataxin(81-210), m81-FXN, FXN, FRDA, X25

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6409b](#) was selected from the C-term region of human FXN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

FXN Antibody (C-term) Blocking Peptide - Protein Information**FXN Antibody (C-term) Blocking Peptide - Background**

FXN is a mitochondrial protein which belongs to the FRATAXIN family. The protein functions in regulating mitochondrial iron transport and respiration. The expansion of intronic trinucleotide repeat GAA results in Friedreich ataxia.

Name FXN**Synonyms** FRDA, X25**Function**

Promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe(2+) to proteins involved in these pathways. May play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe(2+) to Fe(3+); the oligomeric form but not the monomeric form has in vitro ferroxidase activity. May be able to store large amounts of iron in the form of a ferrihydrite mineral by oligomerization; however, the physiological relevance is unsure as reports are conflicting and the function has only been shown using heterologous overexpression systems. Modulates the RNA-binding activity of ACO1.

Cellular Location

Mitochondrion. Cytoplasm, cytosol.
Note=PubMed:18725397 reports localization exclusively in mitochondria.

Tissue Location

Expressed in the heart, peripheral blood lymphocytes and dermal fibroblasts.

FXN Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)